Your session is about to expire
← Back to Search
Loop Diuretic
Furoscix for Heart Failure (RESISTANCE-HF Trial)
Phase 2
Waitlist Available
Led By Ambarish Pandey, MD, MSCS
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights
RESISTANCE-HF Trial Summary
This trial is testing whether the drug Furoscix is more effective than standard care at helping people with heart failure who retain fluid. This will be measured by urine sodium levels.
Who is the study for?
This trial is for English-speaking patients recently hospitalized for acute decompensated heart failure with specific blood markers, who can be screened within two weeks of hospital discharge and have a recent echocardiogram. It's not for those with severe kidney disease, very low blood pressure, recent ICU stay or inotrope use, pregnant women, certain other health conditions or treatments.Check my eligibility
What is being tested?
The study tests if Furoscix is better at removing excess fluid from the body compared to standard diuretic therapy in heart failure patients. Participants are split into groups by chance to receive either Furoscix or their usual care. The main measure of success is how much urine they produce after treatment.See study design
What are the potential side effects?
Potential side effects of Furoscix may include dehydration, electrolyte imbalances (like low potassium), low blood pressure, dizziness upon standing up quickly (orthostatic hypotension), and possible skin irritation where the medication is applied.
RESISTANCE-HF Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Post-treatment diuretic efficiency as measured by cumulative urine output within 1 day.
Post-treatment diuretic efficiency as measured by spot urine sodium levels in 1 day
Secondary outcome measures
Number of participants with post-intervention need for emergency department visit or hospitalization
RESISTANCE-HF Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: > 11 BAN-ADHF, FuroscixExperimental Treatment1 Intervention
Patients with diuretic resistance as determined by a BAN-ADHF score > 11 will receive Furoscix over 5 hours at 8 mg/mL.
Group II: <= 11 BAN-ADHF, FuroscixExperimental Treatment1 Intervention
Patients without diuretic resistance as determined by BAN-ADHF score <= 11 will receive Furoscix over 5 hours at 8 mg/mL.
Group III: <= 11 BAN-ADHF, controlActive Control1 Intervention
Patients without diuretic resistance as determined by BAN-ADHF score <= 11 will receive home dose oral diuretic
Group IV: > 11 BAN-ADHF, controlActive Control1 Intervention
Patients with diuretic resistance as determined by a BAN-ADHF score > 11 will receive home dose oral diuretic.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Loop diuretics, such as those being studied in the Furoscix trial, inhibit sodium and chloride reabsorption in the Loop of Henle, leading to increased urine production and reduced fluid overload. This is essential for heart failure patients as it decreases the volume of blood the heart must pump, reducing the heart's workload and alleviating symptoms like edema and shortness of breath.
Other common treatments include ACE inhibitors, which lower blood pressure and reduce strain on the heart; beta-blockers, which slow the heart rate and decrease its demand for oxygen; and aldosterone antagonists, which prevent fluid retention and further reduce blood pressure. Together, these treatments help improve heart function and patient outcomes.
Find a Location
Who is running the clinical trial?
University of Texas Southwestern Medical CenterLead Sponsor
1,055 Previous Clinical Trials
1,054,799 Total Patients Enrolled
23 Trials studying Heart Failure
13,258 Patients Enrolled for Heart Failure
scPharmaceuticals, Inc.Industry Sponsor
11 Previous Clinical Trials
339 Total Patients Enrolled
9 Trials studying Heart Failure
282 Patients Enrolled for Heart Failure
Ambarish Pandey, MD, MSCSPrincipal InvestigatorUT Southwestern Medical Center
2 Previous Clinical Trials
140 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am severely malnourished.I speak English and was hospitalized for worsening heart failure with high NT-proBNP levels.I have been diagnosed with low-output heart failure.My condition is advanced liver disease.Your top blood pressure number is less than 100.My kidney function is very low or I am in the final stage of kidney disease.There is not enough information about your BAN-ADHF score.I have not been in the ICU in the last 3 months.I can join the study within 14 days of being hospitalized.You are currently using inotropic medications at home.I have not used inotropes in the last 3 months.You have had a heart transplant or have a left ventricular assist device.You had an echocardiogram within the past 6 months.I have been prescribed diuretics to take at home.I am currently taking a diuretic that is not a loop diuretic.You have abnormal levels of electrolytes in your body when you leave the hospital.I do not have skin conditions that prevent Furoscix use.I cannot collect my urine.
Research Study Groups:
This trial has the following groups:- Group 1: <= 11 BAN-ADHF, Furoscix
- Group 2: <= 11 BAN-ADHF, control
- Group 3: > 11 BAN-ADHF, control
- Group 4: > 11 BAN-ADHF, Furoscix
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger